4D Molecular Therapeutics

Dose response demonstrated in favor of highest tested dose of 3E10 vg/eye, including 100% reduction in supplemental anti-VEGF injections (4 of 4 evaluable patients injection-free) and a…

Completed target enrollment of 50 patients in the randomized Phase 2 Dose Expansion stage of the PRISM clinical trial over approximately two quarters, nearly two quarters ahead of initial…

<!-- Name:DistributionId Value:8754801 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

<!-- Name:DistributionId Value:8741968 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

EMERYVILLE, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution…

EMERYVILLE, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT) (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed…

- First-ever clinical activity data reported on 4D-310 Fabry disease product candidate utilizing the proprietary C102 targeted and evolved vector invented through Therapeutic Vector…

4D-125 was well tolerated in all patients treated to-date (n=8), with no dose-limiting toxicities, no serious adverse events and no chronic inflammationClinical activity observed through…